A disease population can be sufficiently stratified into distinct subtypes by a variety of theragnostic methods. This stratified medicine approach leads to providing personalized treatment options in a single patient or subsets of patients.
The primary objective of precision medicine is to achieve cure, remission, excellent response, disease-free or relapse-free survival, etc. in a treated patient or subsets of patients within a defined period. This approach also includes a priori selection of poor responders and non-responders to a treatment such that significant time and money are not wasted.
The managed care model developed by KLĀRITOS achieves significant efficiencies across the entire healthcare system. The value is realized by providing both therapeutic efficacy and financial assurances a priori to a single patient, subsets of patients, or to an entire disease population (e.g., RA).
The meaning of value in healthcare--particularly with specialty drugs remains elusive.
Costs and efficiencies are not systematically addressed in the existing managed care models.
Value includes at least three components: therapeutic efficacy, time cost, and treatment cost that includes both drug & medical spending.
A managed-care model that integrates precision medicine to find this value is truly disruptive.